Xofluza (baloxavir marboxil, Genetech)
Indications: acute uncomplicated influenza in patients 12+, <48hr symptomatic
Dosage:
Contraindications: history of hypersensitivity to baloxair marboxil or any of its ingredients
FDA Issues CRL for Heplisav-B in Adults With ESRD on Hemodialyis
May 14th 2024Dynavax plans to meet with the FDA to discuss how the company can provide additional data to support the approval of its 4-dose Heplisav-B regimen and expand protection for adults with end-stage renal disease (ESRD) on hemodialysis.